GSK PLC (GLAXF)
22.65
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
GSK Revenue (Quarterly): 9.339B for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 9.339B |
December 31, 2023 | 10.00B |
September 30, 2023 | 10.32B |
June 30, 2023 | 8.984B |
March 31, 2023 | 8.449B |
December 31, 2022 | 8.673B |
September 30, 2022 | 9.214B |
June 30, 2022 | 8.711B |
March 31, 2022 | 9.647B |
December 31, 2021 | 9.539B |
September 30, 2021 | 9.137B |
June 30, 2021 | 8.160B |
March 31, 2021 | 10.23B |
December 31, 2020 | -1.327B |
September 30, 2020 | 11.17B |
June 30, 2020 | 9.455B |
March 31, 2020 | 11.65B |
December 31, 2019 | 11.46B |
September 30, 2019 | 11.56B |
June 30, 2019 | 10.04B |
March 31, 2019 | 9.980B |
December 31, 2018 | 10.55B |
September 30, 2018 | 10.54B |
June 30, 2018 | 9.961B |
March 31, 2018 | 10.04B |
Date | Value |
---|---|
December 31, 2017 | 10.14B |
September 30, 2017 | 10.27B |
June 30, 2017 | 9.357B |
March 31, 2017 | 9.145B |
December 31, 2016 | 9.423B |
September 30, 2016 | 9.907B |
June 30, 2016 | 9.383B |
March 31, 2016 | 8.917B |
December 31, 2015 | 9.535B |
September 30, 2015 | 9.494B |
June 30, 2015 | 9.019B |
March 31, 2015 | 8.522B |
December 31, 2014 | 9.786B |
September 30, 2014 | 9.426B |
June 30, 2014 | 9.358B |
March 31, 2014 | 9.287B |
December 31, 2013 | 11.18B |
September 30, 2013 | 10.09B |
June 30, 2013 | 10.17B |
March 31, 2013 | 10.05B |
December 31, 2012 | 10.92B |
September 30, 2012 | 10.31B |
June 30, 2012 | 10.23B |
March 31, 2012 | 10.43B |
December 31, 2011 | 10.96B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-1.327B
Minimum
Dec 2020
11.65B
Maximum
Mar 2020
9.221B
Average
9.497B
Median
Revenue (Quarterly) Benchmarks
Adaptimmune Therapeutics PLC | 5.678M |
Biodexa Pharmaceuticals Plc | -- |
Verona Pharma PLC | -- |
NuCana PLC | -- |
Autolus Therapeutics PLC | 10.09M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 1.327B |
Total Expenses (Quarterly) | 7.449B |
EPS Diluted (Quarterly) | 0.3222 |
Enterprise Value | 108.86B |
Gross Profit Margin (Quarterly) | 73.24% |
Profit Margin (Quarterly) | 14.21% |
Earnings Yield | 5.63% |
Operating Earnings Yield | 8.59% |
Normalized Earnings Yield | 6.218 |